Document Detail


Efficacy and safety of terbinafine 1% solution in the treatment of interdigital tinea pedis and tinea corporis or tinea cruris.
MedLine Citation:
PMID:  11270304     Owner:  NLM     Status:  MEDLINE    
Abstract/OtherAbstract:
Two randomized, double-blind, vehicle-controlled, multicenter studies assessed the efficacy and safety of a new terbinafine 1% solution for the treatment of interdigital tinea pedis and tinea corporis or tinea cruris (tinea corporis/cruris). Patients with interdigital tinea pedis applied terbinafine 1% solution or vehicle twice daily for 1 week with 7 weeks of follow-up (N = 153), and patients with tinea corporis/cruris applied terbinafine 1% solution or vehicle once daily for 1 week with 3 weeks of follow-up (N = 66). Efficacy was assessed mycologically and clinically at the end of treatment and throughout follow-up. In the tinea pedis study, 66% of patients were effectively treated with terbinafine compared with 4% of the group treated by vehicle (P < .001; Mantel-Haenszel test). In the tinea corporis/cruris study, treatment was effective in 65% of the terbinafine group compared with 8% of the vehicle group (P < .001). There were no significant differences in the frequency of cutaneous adverse events between the 2 groups in either study. We conclude that one week of therapy with terbinafine 1% solution is highly effective, superior to vehicle, and safe for use in superficial fungal infections.
Authors:
M Lebwohl; B Elewski; D Eisen; R C Savin
Related Documents :
1596014 - Tuberculous pleural effusion: 6-month therapy with isoniazid and rifampin.
16283214 - Candida glabrata prosthetic valve endocarditis treated successfully with fluconazole pl...
10926104 - Tuberculosis of the skull. a case report and review of the literature.
2838534 - Itraconazole therapy for recalcitrant dermatophyte infections.
23275904 - New mucosal flap modification for endonasal endoscopic dacryocystorhinostomy in asians.
19699154 - Long-term vagus nerve stimulation in the treatment of lennox-gastaut syndrome.
Publication Detail:
Type:  Clinical Trial; Journal Article; Multicenter Study; Randomized Controlled Trial; Research Support, Non-U.S. Gov't    
Journal Detail:
Title:  Cutis     Volume:  67     ISSN:  0011-4162     ISO Abbreviation:  Cutis     Publication Date:  2001 Mar 
Date Detail:
Created Date:  2001-03-28     Completed Date:  2001-07-12     Revised Date:  2013-09-12    
Medline Journal Info:
Nlm Unique ID:  0006440     Medline TA:  Cutis     Country:  United States    
Other Details:
Languages:  eng     Pagination:  261-6     Citation Subset:  IM    
Affiliation:
Mount Sinai Medical Center, 5 E 98th St, 12th Floor, Box 1048, New York, NY 10029, USA.
Export Citation:
APA/MLA Format     Download EndNote     Download BibTex
MeSH Terms
Descriptor/Qualifier:
Administration, Cutaneous
Adolescent
Adult
Aged
Aged, 80 and over
Antifungal Agents / administration & dosage,  therapeutic use*
Child
Double-Blind Method
Female
Humans
Male
Middle Aged
Naphthalenes / administration & dosage,  therapeutic use*
Prospective Studies
Tinea / drug therapy*
Tinea Pedis / drug therapy
Treatment Outcome
United States
Chemical
Reg. No./Substance:
0/Antifungal Agents; 0/Naphthalenes; 91161-71-6/terbinafine

From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine


Previous Document:  Suspected induction of a pyoderma gangrenosum-like eruption due to sulpiride treatment.
Next Document:  Urinary incontinence. No need to be wet and upset.